Literature DB >> 28253521

HIV-Associated Gastrointestinal Cancer.

Björn E-O Jensen, Mark Oette, Johannes Haes, Dieter Häussinger.   

Abstract

People living nowadays with HIV and AIDS may be treated effectively regarding virus replication and immunology. However, non-AIDS-defining cancer is of growing relevance due to high incidence and unfavorable outcome. The aim of this review is to summarize current knowledge on gastrointestinal (GI) carcinoma. Although literature on GI cancer is rare, an increased incidence of esophageal, gastric, pancreatic, hepatocellular, and colorectal carcinoma has been demonstrated. However, there are only few reports on therapy strategies and outcome, so that, despite increased occurrence of many GI carcinomas, only little is known about individualized treatment options and outcome in HIV-positive patients. More efforts have to be undertaken to close this gap.
© 2017 S. Karger GmbH, Freiburg.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28253521     DOI: 10.1159/000456714

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  3 in total

Review 1.  Molecular Pathogenesis of Cholangiocarcinoma.

Authors:  Peter L Labib; George Goodchild; Stephen P Pereira
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

2.  Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada.

Authors:  Maryam Darvishian; Zahid A Butt; Stanley Wong; Eric M Yoshida; Jaskaran Khinda; Michael Otterstatter; Amanda Yu; Mawuena Binka; Carmine Rossi; Geoff McKee; Margo Pearce; Maria Alvarez; Jason Wong; Darrel Cook; Troy Grennan; Jane Buxton; Mark Tyndall; Ryan Woods; Mel Krajden; Parveen Bhatti; Naveed Z Janjua
Journal:  Ther Adv Med Oncol       Date:  2021-02-11       Impact factor: 8.168

3.  Molecular profiling of gastric cancer in a population with high HIV prevalence reveals a shift to MLH1 loss but not the EBV subtype.

Authors:  Violet Kayamba; Julia Butt; Tim Waterboer; Ellen Besa; Naheed Choudhry; Anglin Hamasuku; Peter Julius; Douglas C Heimburger; Masharip Atadzhanov; Paul Kelly
Journal:  Cancer Med       Date:  2020-03-24       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.